PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25470432-8	2015	In both cells, the expressions of CYP2C8, CYP2C9, CYP3A4 and constitutive androstane receptor (CAR) were decreased by MTZ treatment.	Metronidazole	118-121	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	50-56	
15855244-8	2005	The possible mechanism may be related to metronidazole"s weak inhibition of CYP3A4 and, possibly, P-glycoprotein.	Metronidazole	41-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82	
11151744-1	2000	OBJECTIVE: Case reports have described elevated concentrations of CYP3A4 substrates (e.g. cyclosporin) during metronidazole treatment.	Metronidazole	110-123	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	66-72	
11151744-2	2000	Therefore, we wanted to study whether metronidazole affects CYP3A4 activity, using midazolam as a model substrate in vitro and in vivo.	Metronidazole	38-51	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	60-66	
10917381-8	2000	A contributing factor in this case may have been the concomitant administration of metronidazole, which inhibits the cytochrome P450 enzyme (CYP3A4) also responsible for the metabolism of quetiapine.	Metronidazole	83-96	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	141-147	
18048573-1	2007	Recent case reports suggest that addition of high-dose metronidazole might be associated with elevated plasma concentrations of substrates of cytochrome P450 (CYP) 3A.	Metronidazole	55-68	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-166	
17374625-0	2007	Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway?	Metronidazole	5-18	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-38	
17374625-2	2007	OBJECTIVE: To explore whether CYP3A inhibition by metronidazole is the primary mechanism by which metronidazole interacts with coadministered CYP3A substrates.	Metronidazole	50-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35	
17374625-2	2007	OBJECTIVE: To explore whether CYP3A inhibition by metronidazole is the primary mechanism by which metronidazole interacts with coadministered CYP3A substrates.	Metronidazole	50-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-147	
17374625-2	2007	OBJECTIVE: To explore whether CYP3A inhibition by metronidazole is the primary mechanism by which metronidazole interacts with coadministered CYP3A substrates.	Metronidazole	98-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	30-35	
17374625-2	2007	OBJECTIVE: To explore whether CYP3A inhibition by metronidazole is the primary mechanism by which metronidazole interacts with coadministered CYP3A substrates.	Metronidazole	98-111	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	142-147	
17374625-8	2007	DATA SYNTHESIS: Elevated plasma concentrations and toxicities have been reported for a number of CYP3A substrates including amiodarone, carbamazepine, quinidine, tacrolimus, and cyclosporine when administered with metronidazole.	Metronidazole	214-227	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	97-102	
17374625-9	2007	This has led to the widespread belief that metronidazole is a significant inhibitor of CYP3A4.	Metronidazole	43-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-93	
17374625-11	2007	CONCLUSIONS: Drug interactions between metronidazole and certain CYP3A substrates do not appear to result from CYP3A4/5 inhibition by metronidazole.	Metronidazole	39-52	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-70	
17374625-12	2007	Until any mechanism is identified by which metronidazole alters the disposition of certain CYP3A substrates, drug interactions with this agent should be assessed on a case-by-case basis, taking into account the safety index of the coadministered drug and the availability of equally effective substitutes for either metronidazole or the drug with which it putatively interacts.	Metronidazole	43-56	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96	
11601665-0	2001	Effects of metronidazole on hepatic CYP3A4 activity.	Metronidazole	11-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42	
11601665-1	2001	STUDY OBJECTIVE: To evaluate the effect of a short course of oral metronidazole, commonly used for bowel-preparation regimens, on hepatic cytochrome P450 (CYP) 3A4 activity, as measured by the [14C N-methyl]-erythromycin breath test (ERMBT) in healthy volunteers.	Metronidazole	66-79	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	138-163